SCHEMBL30289641

SCHEMBL30289641

Cc1cc(SC#N)ccc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.46
MAPT P10636 7/20 0.46
GFER P55789 1/20 0.46
POLB P06746 1/20 0.43
HTT P42858 1/20 0.42
CA2 P00918 1/20 0.40
CA5A P35218 1/20 0.40
LMNA P02545 3/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
GABRA1 P14867 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA2 P47869 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
HAO1 Q9UJM8 1/20 0.33
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21224393 1.00 ALDH1A1 (0.46) ALDH1A1MAPTGFERPOLBHTT
SCHEMBL12642657 0.81 ALDH1A1 (0.50) ALDH1A1MAPTGFERPOLBHTT
SCHEMBL16707551 0.78 ALDH1A1 (0.47) ALDH1A1MAPTGFERPOLBHTT
SCHEMBL10595472 0.76 ALDH1A1 (0.40) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL10341619 0.76 ALDH1A1 (0.40) ALDH1A1MAPTLMNASMN1; SMN2NPC1
SCHEMBL944163 0.76 ALDH1A1 (0.50) ALDH1A1MAPTGFERPOLBHTT
SCHEMBL24575343 0.76 AR (0.41) ALDH1A1MAPTPOLBCA2CA5A
SCHEMBL387936 0.74 ALDH1A1 (0.40) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL29421569 0.74 ALDH1A1 (0.40) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL7459101 0.73 ALDH1A1 (0.44) ALDH1A1MAPTGFERPOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179082-A1 IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER Mirati Therapeutics, Inc. 2025-06-05 US disclosed
WO-2025043191-A1 PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE ORIC PHARMACEUTICALS, INC. (US) 2025-02-27 WO disclosed
EP-4404932-A1 PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS Oric Pharmaceuticals, Inc. (US) 2024-07-31 EP disclosed
WO-2023049723-A1 PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS ORIC PHARMACEUTICALS, INC. (US) 2023-03-30 WO disclosed
WO-2023049724-A1 PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS ORIC PHARMACEUTICALS, INC. (US) 2023-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179082-A1 IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER BMI1, EZH2, SUZ12 ALDH1A1 644/4885MAPT 4210/4885GFER 3968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.